To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cas No.: | 1034190-08-3 |
| Chemical Name: | (S)-3-(2-aMino-3-MethylbutanaMido)propane-1-sulfonic acid |
| Synonyms: | ALZ-801,ALZ801,ALZ 801 |
| SMILES: | C(S(O)(=O)=O)CCNC(=O)[C@H](N)C(C)C |
| Formula: | C8H18N2O4S |
| M.Wt: | 238.302 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Publication: | 1. Kocis P, et al. CNS Drugs. 2017 Jun;31(6):495-509. 2. Hey JA, et al. Clin Pharmacokinet. 2018 Mar;57(3):315-333. |
| Description: | ALZ-801 is an orally available, small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated prodrug of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound[1]. ALZ-801 is an advanced and markedly improved clinical candidate for the treatment of Alzheimer’s disease[2]. |
| Target: | β-amyloid[1] |
| References: | [1]. John A. Hey, et al. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain. CNS Drugs. 2018; 32(9): 849–861. [2]. Hey JA, et al. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease. Clin Pharmacokinet. 2018 Mar;57(3):315-333. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|